Regarding "Hepatitis B Surface Antigen Positivity Is an Independent Unfavorable Prognostic Factor in Diffuse Large B-Cell Lymphoma in the Rituximab Era"

Marco Picardi; Claudia Giordano; Roberta Della Pepa; Novella Pugliese; Aldo Leone; Giuseppe Delle Cave; Rossella Iula; Fabrizio Pane; Giuseppe Gentile

doi:10.1002/onco.13710

Regarding "Hepatitis B Surface Antigen Positivity Is an Independent Unfavorable Prognostic Factor in Diffuse Large B-Cell Lymphoma in the Rituximab Era"

Oncologist. 2021 Jun;26(6):e1083-e1084. doi: 10.1002/onco.13710. Epub 2021 Feb 24.

Authors

Marco Picardi¹, Claudia Giordano¹, Roberta Della Pepa¹, Novella Pugliese¹, Aldo Leone¹, Giuseppe Delle Cave¹, Rossella Iula¹, Fabrizio Pane¹, Giuseppe Gentile²

Affiliations

¹ Department of Clinical Medicine and Surgery, Hematology Unit, Federico II University Medical School, Naples, Italy.
² Department of Translational and Precision Medicine Sapienza Università di Roma, Rome, Italy.

Abstract

This letter to the editor remarks on the article by Cheng et al., which reported results of a retrospective study that assessed 5‐year progression‐free and overall survival (OS) of 98 patients with hepatitis B surface antigen–seropositive patients receiving R‐CHOP‐21 as remission induction for diffuse large B‐cell lymphoma.

Trial registration: ClinicalTrials.gov NCT03804372.

Publication types

Letter
Comment

MeSH terms

Hepatitis B Surface Antigens*
Humans
Lymphoma, Large B-Cell, Diffuse* / drug therapy
Prognosis
Rituximab / therapeutic use
Vincristine

Substances

Hepatitis B Surface Antigens
Rituximab
Vincristine

Associated data

ClinicalTrials.gov/NCT03804372
EudraCT/2019-000159-14